Hyperuricemia on Hypertension and Metabolic Syndrome

Instituto Nacional de Cardiologia Ignacio Chavez40 enrolled

Overview

The purpose of this study is to evaluate the influence of hyperuricemia treatment compared with placebo on participants with high risk of hypertension and metabolic syndrome.

Elevated consumption of high fructose corn syrup has lead to an increase of 30% of fructose intake since the last 20 years. Important data supporting this fact can be reflected on incidence and prevalence of Metabolic syndrome and hyperuricemia. A peculiar effect of fructose intake demonstrated in animal models is the development of elevated uric acid levels; also some studies have found a clear association between hyperuricemia as an important risk factor for hypertension, diabetes mellitus, chronic kidney disease and metabolic syndrome. Taking into account the existing evidence, our clinical research team presents this protocol as a way to evaluate the effect of uric acid treatment and its relation with Fructose consumption, metabolic syndrome parameters, hyperuricemia and risk of hypertension. Confirming evidence with clinical basis may be the initial strategy to create primary prevention programs to control this health problems affecting Mexican Population.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

QUADRUPLE

Enrollment

Conditions

Systolic and Diastolic Blood Pressure Levels Uric Acid Levels Metabolic Syndrome Parameters Hepatic Enzymes

Interventions

AllopurinolDRUG

daily dosage

placeboOTHER

daily dosage

Eligibility

Sex: ALLMin age: 25 YearsMax age: 60 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * adults with blood pressure from 120/80 mmHg and less than 140/90 mmHg * no pharmacological treatment for blood pressure control Exclusion Criteria: * hypertension (more than 140/90mmHg) * Diabetes Mellitus type 1 or 2 * Chronic kidney disease (MDRD less than 60) * Hepatic Disease * Malignancy * Pregnancy * patient receiving any medication

Locations (1)

Insituto Nacional de Cardiología Ignacio Chávez

México, State of Mexico, Mexico

Outcomes

Primary Outcomes

Effect of hyperuricemia treatment on systemic blood pressure

participants will be randomized to a 4 week placebo versus alopurinol treatment followed by a wash out period. After crossover them, they will receive the complementary pharmacological intervention for another 4 weeks.

Time frame: 14 weeks

Secondary Outcomes

Effect of hyperuricemia treatment on metabolic syndrome parameters

baseline and final laboratory samples during pre and post crossover periods will include metabolic syndrome measurements (triglycerides, cholesterol, glucose and abdominal perimeter).

Time frame: 14 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.